**Core Concept**
Bortezomib, also known as Boezomib, is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It works by blocking the action of proteasomes, which are protein complexes responsible for degrading unneeded or damaged proteins within cells.

**Why the Correct Answer is Right**
Bortezomib specifically targets the 26S proteasome, a large protein complex involved in protein degradation. By inhibiting the proteasome, bortezomib disrupts the cell's ability to degrade proteins, leading to an accumulation of defective proteins and ultimately inducing apoptosis in cancer cells. This mechanism is particularly effective in multiple myeloma and mantle cell lymphoma, where the cancer cells are highly dependent on proteasome function.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because bortezomib is not primarily used for the treatment of colorectal cancer. While it may be used in combination with other therapies, it is not a first-line treatment for this disease.
**Option B:** This option is incorrect because bortezomib is not a tyrosine kinase inhibitor. Tyrosine kinase inhibitors are a different class of cancer therapies that target specific enzymes involved in cell signaling.
**Option C:** This option is incorrect because bortezomib is not used for the treatment of breast cancer. While it may be used in combination with other therapies for certain subtypes of breast cancer, it is not a standard treatment for this disease.

**Clinical Pearl / High-Yield Fact**
Bortezomib is often used in combination with other therapies, such as dexamethasone and melphalan, to treat multiple myeloma. This combination can significantly improve outcomes for patients with this disease.

**Correct Answer:** D. Multiple myeloma.